Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

The trajectory of B-cell immunity six months after mRNA vaccination

Researchers assess SARS-CoV-2 antibodies in individuals vaccinated with a mRNA COVID-19 vaccine six months after receiving their second dose.

10 Mar 2022

Durable selenium nanoparticle fabrics with antiviral and antibacterial properties

Researchers graft SeNPs on polyester fabric through a flat screen-printing technique and observed their antimicrobial activity.

8 Mar 2022

Current and future perspectives of mRNA technology

New research reports on the current and future perspectives on messenger ribonucleic acid technology, the platform on which the first successful COVID-19 vaccine was based.

8 Mar 2022

Biodegradable nanoparticle used in medical sutures could help combat scleroderma

Investigators have discovered that a biodegradable nanoparticle used in medical sutures could combat a rare, sometimes-fatal autoimmune disease.

7 Mar 2022

Current progress in SARS-CoV-2 vaccine candidates

In a new study, researchers illustrated the current progress and obstacles in COVID-19 vaccine development.

7 Mar 2022

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

Application of various nanoparticle-capsulated siRNA as therapeutics for SARS-CoV-2 infection

In a review published in the International Journal of Molecular Sciences, researchers have been reviewing the use of siRNAs to target coronaviruses.

25 Feb 2022

A comparison of COVID-19 vaccines by neutralizing antibody potency

Researchers use an international standardized assessment method to compare the efficacy of antibody responses to the major COVID-19 vaccines.

24 Feb 2022

Exploring the potential of mosaic RBD nanoparticles to fight SARS-CoV-2

Researchers explore the potential of mosaic receptor-binding domain nanoparticles in protective immunity against SARS-CoV-2

22 Feb 2022

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a new manuscript, Exosome mediated genetic reprogramming of tumor associated macrophages by exoASO-STAT6 leads to potent monotherapy anti-tumor efficacy, in the American Association for the Advancement of Science's journal, Science Advances.

18 Feb 2022

Intermediate size nanoparticles may be effective at stopping internal bleeding

Traumatic injuries are the leading cause of death in the U.S. among people 45 and under, and such injuries account for more than 3 million deaths per year worldwide.

17 Feb 2022

Detection of SARS-CoV-2 RNA by plasmonic-magnetic nanorobots

Researchers present a simple and efficient plasmonic-magnetic nanorobot for the detection of SARS-CoV-2 RNA.

16 Feb 2022

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

A new study explored the high immunogenicity and stability of lyophilized mRNA-LNP vaccines in relation to SARS-CoV-2.

16 Feb 2022

Variations in the neutralization of SARS-CoV-2 variants in vaccinated mice and primates

In a new study, researchers demonstrated the variations in the neutralizing antibody responses induced by SARS-CoV-2 vaccines in humans, non-human primates, and mice against the SARS-CoV-2 variants of concern.

14 Feb 2022

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted mRNA-1273.529 vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 Omicron infection in mice.

14 Feb 2022

Nanoparticle vaccine effective against eight SARS-CoV-2 variants in non-human primates

Researchers demonstrate that SARS-CoV-2 RBD-based nanoparticle vaccine induces neutralizing antibodies against SARS-CoV-2 variants.

2 Feb 2022

New nanoparticle SARS-CoV-2 vaccine shows stronger, broader, and more durable protection

The first generation of COVID-19 vaccines have been highly effective, but also have limitations: their efficacy can wane without a booster shot, and they may be less effective against some variants.

2 Feb 2022

Developing post-vaccination SARS-CoV-2 standard reference sera

A new study reports the generation of reference sera reagents that were obtained from subjects vaccinated with one of four COVID-19 vaccines.

1 Feb 2022

Study highlights importance of immunizing and boosting PAD syndromes patients with SARS-CoV-2 mRNA vaccines

A new study posted to the medRxiv* preprint server has evaluated the effect of mRNA-based COVID-19 vaccination and boosting strategy on serum antibody responses in PAD patients against the original SARS-CoV-2 strain and circulating variants.

31 Jan 2022

New approach to make RNA vaccines easier to swallow

Like most vaccines, RNA vaccines have to be injected, which can be an obstacle for people who fear needles. Now, a team of MIT researchers has developed a way to deliver RNA in a capsule that can be swallowed, which they hope could help make people more receptive to them.